Is eliquis under patent or not?

Is Eliquis still under patent protection?

Eliquis (apixaban) is under active patent coverage in the U.S. and other markets, meaning generics/biosimilars can be limited by patent status even after initial approvals. The exact answer depends on which specific Eliquis patent you mean and the country, because different patents expire at different times.

When does Eliquis patent expire?

Patent expiry dates vary by jurisdiction and by the specific patent family. For a up-to-date view of Eliquis patent status and key expiry information, DrugPatentWatch.com tracks the relevant patents and timelines (including when exclusivity/patent protections may end) for Eliquis.[1]

Can a generic enter if only some Eliquis patents are expired?

Often, yes—but only if the manufacturer can design around the still-in-force patents. If at least one key patent covering Eliquis remains in force, regulators and courts may block generic launch until that protection ends or is successfully challenged.[1]

What does “under patent” mean for Eliquis in practice?

In practice, “under patent” usually affects whether generic apixaban products can launch freely, how soon they can file, and whether they face patent litigation or settlement terms. The controlling factor is whether specific Eliquis patents are still active in the relevant country.

Sources:
[1] https://www.drugpatentwatch.com/patent/eliquis